Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Lowered by BidaskClub

Esperion Therapeutics (NASDAQ:ESPR) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Wednesday, BidAskClub reports.

A number of other equities analysts also recently weighed in on ESPR. Cowen restated a “buy” rating and issued a $80.00 target price on shares of Esperion Therapeutics in a research note on Thursday, July 18th. Citigroup set a $73.00 target price on Esperion Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Goldman Sachs Group downgraded Esperion Therapeutics from a “neutral” rating to a “sell” rating and set a $50.00 target price on the stock. in a research note on Wednesday, May 29th. Northland Securities set a $65.00 target price on Esperion Therapeutics and gave the stock a “buy” rating in a research note on Friday, June 14th. Finally, Stifel Nicolaus restated a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, June 13th. Three research analysts have rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $74.00.

ESPR stock traded down $0.57 during mid-day trading on Wednesday, reaching $38.21. 13,425 shares of the company traded hands, compared to its average volume of 370,456. The firm has a market cap of $1.04 billion, a PE ratio of -5.06 and a beta of 1.72. Esperion Therapeutics has a fifty-two week low of $36.06 and a fifty-two week high of $60.99. The company has a 50 day simple moving average of $46.10.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $2.43. The business had revenue of $145.42 million during the quarter, compared to analysts’ expectations of $69.35 million. During the same quarter in the previous year, the firm earned ($1.73) EPS. Analysts predict that Esperion Therapeutics will post -2.56 EPS for the current fiscal year.

In related news, CEO Timothy M. Mayleben purchased 5,000 shares of the stock in a transaction that occurred on Friday, June 28th. The shares were bought at an average price of $46.00 per share, with a total value of $230,000.00. Following the acquisition, the chief executive officer now owns 66,163 shares of the company’s stock, valued at approximately $3,043,498. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Target N. V. Biotech purchased 50,000 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The stock was bought at an average cost of $42.65 per share, for a total transaction of $2,132,500.00. Following the acquisition, the insider now directly owns 3,572,964 shares in the company, valued at approximately $152,386,914.60. The disclosure for this purchase can be found here. Insiders own 7.70% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Aperio Group LLC bought a new stake in Esperion Therapeutics during the 2nd quarter valued at $29,000. Advisor Group Inc. raised its holdings in Esperion Therapeutics by 44.4% during the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 291 shares during the period. Parallel Advisors LLC bought a new stake in Esperion Therapeutics during the 1st quarter valued at $80,000. Marshall Wace North America L.P. bought a new stake in Esperion Therapeutics during the 1st quarter valued at $164,000. Finally, Steward Partners Investment Advisory LLC bought a new stake in Esperion Therapeutics during the 2nd quarter valued at $165,000.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Read More: What are no-load funds?

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.